|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||10.26 / 34.99|
Morgan Stanley believes these stocks will have negative earnings catalysts, but how does the technical analysis stack up?
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Relypsa, Inc.
Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Shares of Relypsa surged on news of a takeover by Galenica, the owner of Switzerland's biggest pharmacy network.
Rigrodsky & Long, P.A.
Shares of Relypsa are rallying after the company announced it has agreed to be acquired by Galenica Group in a $1.53B deal.
Relypsa (RLYP) stock is up in early morning trading on Thursday after Galenica agreed to purchase the biotech for $1.53 billion.
General Motors crushed Wall Street earnings estimates before the opening bell.
The Swiss buyer will gain better U.S. access and drugs including Veltassa, which treats high blood potassium levels.
After a big run-up, the market behaved in typical fashion -- no damage done.
The most recent short interest data was recently released for the 06/30/2016 settlement date, and Relypsa, Inc is one of the most shorted stocks of the Russell 3000, based on 6.01 "days to cover" versus the median component at 4.51. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
In trading on Friday, shares of Relypsa, Inc crossed above their 200 day moving average of $18.92, changing hands as high as $19.29 per share. Relypsa, Inc shares are currently trading up about 1.9% on the day.
Biotech stocks remain pressured following the recent Brexit vote, which will make investing in these already highly volatile stocks even trickier. But there are opportunities too.
Updates on smaller housing, retail and biotech plays recently mentioned on these pages.
These mid-caps would do well by themselves, but could tempt bigger companies.